+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Castrate-resistant Prostate Cancer Market By Therapy (Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy), By Region, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5241444
  • Report
  • January 2021
  • Region: Global
  • 124 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Abbott Laboratories
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Bayer AG
  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
The Global Castrate-resistant Prostate Cancer Market size is expected to reach $14.5 billion by 2026, rising at a market growth of 8.3% CAGR during the forecast period. Castrate-Resistant Prostate Cancer (CRPC), a variety of prostate cancer that generally recurs after managing androgen deprivation therapy (ADC), is getting prominent in the prostate cancer market.

The global market of CRPC is estimated to rise at a notable rate, due to high unmet clinical requirements, increasing prevalence rates, limited survival benefits, and fast-emerging treatment modifications. The market growth will depend on the unique breakthrough treatments responsible for securing survival benefits. The survival benefit is helpful in controlling the peak sales and market penetration of novel approved drugs.

Shifting treatment patterns, arising untapped non-metastatic CRPC space, promising drug pipeline, and increased patient awareness are the factors that are estimated to propel the market growth. Moreover, the untapped CRPC market in the Asia-Pacific and LAMEA region will also boost the overall market growth over the forecast period. Untapped non-metastatic CRPC settings will further accelerate the market growth. However, factors like uncertain reimbursement policies, premium pricing of CRPC drugs, and lack of distinction in the mechanism of action between the approved and novel agents are expected to restrain the market growth.

The increasing prevalence of castrate-resistant prostate cancer, rising adoption of novel drugs, coupled with an unhealthy lifestyle are the main factors predicted to boost the market growth. The requirement for fast treatment alternatives and funding in R&D by leading companies will also contribute to the growth of the market.



By Therapy

Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. The hormonal therapy category garnered the highest revenue share in the castrate-resistant prostate cancer market in 2019. This growth is due to the presence of a huge number of approved drugs, the introduction of new drugs, and the growth of the product portfolio. Additionally, the growing advancement of innovative medicines to fulfill unmet requirements and current treatment options is estimated to propel the growth of the market for castrate-resistant prostate cancer.



By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America recorded the highest revenue share in the castrate-resistant prostate cancer market in 2019 and is estimated to sustain the figures during the forecast period. This growth is due to the high prevalence of the disease, the existence of regional players, and supportive reimbursement policies. Changing lifestyle is another factor that adds to the prevalence of diseases.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.).

Strategies deployed in Castrate-resistant Prostate Cancer Market

Dec-2019: Pfizer Inc. and Astellas Pharma Inc. announced that FDA approved their supplemental New Drug Application (sNDA) for XTANDI (enzalutamide). This has been used for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Oct-2019: The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it received the approval from FDA for its Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor. This inhibitor is used for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Jul-2019: Bayer AG got FDA approval for Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi) product. This product is used for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Mar-2019: Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi) product of Bayer AG got approval from European Commission. This product is used for the treatment of men with non-metastatic castration-resistant prostate cancer.

Jun-2018: Astellas Pharma launched 40 mg XTANDI (generic name enzalutamide) Tablets and 80 mg XTANDI Tablets in Japan for the treatment of castration-resistant prostate cancer.

Feb-2018: The Janssen Pharmaceutical Companies of Johnson & Johnson announced that FDA approved its ERLEADA (apalutamide), a next-generation androgen receptor inhibitor. The inhibitor is used for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).

Dec-2016: Sanofi Genzyme, business unit of Sanofi announced agreement with Scottish Medicines Consortium (SMC). Following this agreement, Jevtana (cabazitaxel), a product of Sanofi is being used in NHS Scotland for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) by Scottish Medicines Consortium (SMC).

Scope of the Study

Market Segments covered in the Report:

By Therapy
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • Radiotherapy
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Sanofi S.A.
  • Johnson and Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC (GSK)
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Bayer AG
  • GlaxoSmithKline PLC (GSK)
  • Johnson and Johnson
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Castrate-resistant Prostate Cancer Market, by Therapy
1.4.2 Global Castrate-resistant Prostate Cancer Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market

Chapter 4. Global Castrate-resistant Prostate Cancer Market by Therapy
4.1 Global Hormonal Therapy Market by Region
4.2 Global Immunotherapy Market by Region
4.3 Global Chemotherapy Market by Region
4.4 Global Radiotherapy Market by Region

Chapter 5. Global Castrate-resistant Prostate Cancer Market by Region
5.1 North America Castrate-resistant Prostate Cancer Market
5.1.1 North America Castrate-resistant Prostate Cancer Market by Therapy
5.1.1.1 North America Hormonal Therapy Market by Country
5.1.1.2 North America Immunotherapy Market by Country
5.1.1.3 North America Chemotherapy Market by Country
5.1.1.4 North America Radiotherapy Market by Country
5.1.2 North America Castrate-resistant Prostate Cancer Market by Country
5.1.2.1 US Castrate-resistant Prostate Cancer Market
5.1.2.1.1 US Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.2 Canada Castrate-resistant Prostate Cancer Market
5.1.2.2.1 Canada Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.3 Mexico Castrate-resistant Prostate Cancer Market
5.1.2.3.1 Mexico Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.4 Rest of North America Castrate-resistant Prostate Cancer Market
5.1.2.4.1 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy
5.2 Europe Castrate-resistant Prostate Cancer Market
5.2.1 Europe Castrate-resistant Prostate Cancer Market by Therapy
5.2.1.1 Europe Hormonal Therapy Market by Country
5.2.1.2 Europe Immunotherapy Market by Country
5.2.1.3 Europe Chemotherapy Market by Country
5.2.1.4 Europe Radiotherapy Market by Country
5.2.2 Europe Castrate-resistant Prostate Cancer Market by Country
5.2.2.1 Germany Castrate-resistant Prostate Cancer Market
5.2.2.1.1 Germany Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.2 UK Castrate-resistant Prostate Cancer Market
5.2.2.2.1 UK Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.3 France Castrate-resistant Prostate Cancer Market
5.2.2.3.1 France Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.4 Russia Castrate-resistant Prostate Cancer Market
5.2.2.4.1 Russia Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.5 Spain Castrate-resistant Prostate Cancer Market
5.2.2.5.1 Spain Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.6 Italy Castrate-resistant Prostate Cancer Market
5.2.2.6.1 Italy Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.7 Rest of Europe Castrate-resistant Prostate Cancer Market
5.2.2.7.1 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy
5.3 Asia Pacific Castrate-resistant Prostate Cancer Market
5.3.1 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
5.3.1.1 Asia Pacific Hormonal Therapy Market by Country
5.3.1.2 Asia Pacific Immunotherapy Market by Country
5.3.1.3 Asia Pacific Chemotherapy Market by Country
5.3.1.4 Asia Pacific Radiotherapy Market by Country
5.3.2 Asia Pacific Castrate-resistant Prostate Cancer Market by Country
5.3.2.1 China Castrate-resistant Prostate Cancer Market
5.3.2.1.1 China Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.2 Japan Castrate-resistant Prostate Cancer Market
5.3.2.2.1 Japan Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.3 India Castrate-resistant Prostate Cancer Market
5.3.2.3.1 India Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.4 South Korea Castrate-resistant Prostate Cancer Market
5.3.2.4.1 South Korea Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.5 Singapore Castrate-resistant Prostate Cancer Market
5.3.2.5.1 Singapore Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.6 Malaysia Castrate-resistant Prostate Cancer Market
5.3.2.6.1 Malaysia Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.7 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market
5.3.2.7.1 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
5.4 LAMEA Castrate-resistant Prostate Cancer Market
5.4.1 LAMEA Castrate-resistant Prostate Cancer Market by Therapy
5.4.1.1 LAMEA Hormonal Therapy Market by Country
5.4.1.2 LAMEA Immunotherapy Market by Country
5.4.1.3 LAMEA Chemotherapy Market by Country
5.4.1.4 LAMEA Radiotherapy Market by Country
5.4.2 LAMEA Castrate-resistant Prostate Cancer Market by Country
5.4.2.1 Brazil Castrate-resistant Prostate Cancer Market
5.4.2.1.1 Brazil Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.2 Argentina Castrate-resistant Prostate Cancer Market
5.4.2.2.1 Argentina Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.3 UAE Castrate-resistant Prostate Cancer Market
5.4.2.3.1 UAE Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.4 Saudi Arabia Castrate-resistant Prostate Cancer Market
5.4.2.4.1 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.5 South Africa Castrate-resistant Prostate Cancer Market
5.4.2.5.1 South Africa Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.6 Nigeria Castrate-resistant Prostate Cancer Market
5.4.2.6.1 Nigeria Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.7 Rest of LAMEA Castrate-resistant Prostate Cancer Market
5.4.2.7.1 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy

Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
Note: Product cover images may vary from those shown
  • Sanofi S.A.
  • Johnson and Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC (GSK)
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll